CN1148338A - 用羟酸酯提高胎儿血红蛋白水平 - Google Patents

用羟酸酯提高胎儿血红蛋白水平 Download PDF

Info

Publication number
CN1148338A
CN1148338A CN95192966A CN95192966A CN1148338A CN 1148338 A CN1148338 A CN 1148338A CN 95192966 A CN95192966 A CN 95192966A CN 95192966 A CN95192966 A CN 95192966A CN 1148338 A CN1148338 A CN 1148338A
Authority
CN
China
Prior art keywords
group
butanoic acid
butyl
ethyl
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN95192966A
Other languages
English (en)
Chinese (zh)
Inventor
埃达·里菲利
A·努迪尔曼
M·沙克来
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1148338A publication Critical patent/CN1148338A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pyrane Compounds (AREA)
CN95192966A 1994-03-07 1995-03-06 用羟酸酯提高胎儿血红蛋白水平 Pending CN1148338A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/206,690 US5569675A (en) 1994-03-07 1994-03-07 Methods of using carboxylic acid esters to increase fetal-hemoglobin levels
US08/206,690 1994-03-07

Publications (1)

Publication Number Publication Date
CN1148338A true CN1148338A (zh) 1997-04-23

Family

ID=22767519

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95192966A Pending CN1148338A (zh) 1994-03-07 1995-03-06 用羟酸酯提高胎儿血红蛋白水平

Country Status (11)

Country Link
US (1) US5569675A (OSRAM)
EP (1) EP0793488A1 (OSRAM)
JP (1) JPH09510202A (OSRAM)
KR (1) KR970701540A (OSRAM)
CN (1) CN1148338A (OSRAM)
AU (1) AU1980695A (OSRAM)
BR (1) BR9507010A (OSRAM)
CA (1) CA2184695A1 (OSRAM)
IL (1) IL112896A0 (OSRAM)
MX (1) MX9603885A (OSRAM)
WO (1) WO1995024189A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880152A (en) * 1995-10-06 1999-03-09 Vertex Pharmaceuticals, Inc. Butyrate prodrugs derived from lactic acid
US5883123A (en) * 1995-10-06 1999-03-16 Vertex Pharmaceuticals, Inc. Butyrate prodrugs derived from lactic acid
US5912269A (en) * 1996-04-30 1999-06-15 Vertex Pharmaceuticals, Inc. Butyrate prodrugs derived from lactic acid
US5827544A (en) * 1995-10-10 1998-10-27 The Arab Pharmaceutical Manufacturing Co. Ltd. Different way of management of neonatal hyperbilirubinemia
US5763488A (en) * 1995-10-30 1998-06-09 Vertex Pharmaceuticals Incorporated Methods and compositions using butyrate esters of threitol
CN1109545C (zh) * 1996-12-13 2003-05-28 科学与工业研究会 螯合铁的制剂及其制备方法
US6130248A (en) * 1996-12-30 2000-10-10 Bar-Ilan University Tricarboxylic acid-containing oxyalkyl esters and uses thereof
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6110970A (en) * 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Nitrogen-containing oxyalkylene esters and uses thereof
US6030961A (en) * 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6110955A (en) * 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Metabolically stabilized oxyalkylene esters and uses thereof
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6124495A (en) * 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US6225350B1 (en) 1998-03-10 2001-05-01 Vertex Pharmaceuticals, Inc. Butyrate prodrugs derived from lactic acid
KR100702823B1 (ko) * 1999-02-05 2007-04-06 베일러 리서치 인스티튜트 Ｃ7 지방산 함유 트리글리세라이드를 포함하는 영양보충물 또는 약제학적 제제
US20030162833A1 (en) 2001-08-01 2003-08-28 Roe Charles R. Fatty acid treatment for cardiac patients
US6693132B2 (en) * 2000-12-21 2004-02-17 Beacon Laboratories, Inc. Methods for using alkanoyloxymethyl esters
US6720445B2 (en) 2000-12-21 2004-04-13 Beacon Laboratories, Inc. Acetyloxymethyl esters and methods for using the same
ITTO20020684A1 (it) * 2002-07-31 2004-02-01 Associazione Veneta Per La Lotta Alla Talassemia Nuovo uso dell'angelicina e di suoi analoghi strutturali.
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005011696A1 (en) * 2003-08-01 2005-02-10 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007011626A2 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20070185045A1 (en) * 2006-02-06 2007-08-09 Ratcliffe Peter J Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
EP2023913A2 (en) 2006-05-09 2009-02-18 Colorado State University Research Foundation Methods for treating blood disorders
US9095565B2 (en) * 2006-05-09 2015-08-04 Phoenicia Biosciences, Inc. Methods for treating blood disorders
WO2007140335A2 (en) * 2006-05-25 2007-12-06 The Regents Of The University Of Michigan Screening methods and transgenic animals for treatment of beta-globin related diseases and conditions
US20110015168A1 (en) * 2007-01-19 2011-01-20 Mitchell Keegan Methods for increasing levels of human fetal hemoglobin
CA2766643C (en) 2009-07-08 2017-01-03 Dermira (Canada), Inc. Tofa analogs useful in treating dermatological disorders or conditions
US9713602B1 (en) * 2016-03-15 2017-07-25 National Sun Yat-Sen University Method for facilitating the oxygen release of hemoglobin-based blood substitutes
WO2018140934A1 (en) 2017-01-30 2018-08-02 The Children's Hospital Of Philadelphia Compositions and methods for hemoglobin production

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025029A (en) * 1986-10-10 1991-06-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
US4822821A (en) * 1986-10-10 1989-04-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
EP0302349B1 (en) * 1987-07-30 1993-09-29 Bar Ilan University Biologically active carboxylic acid esters
US5216004A (en) * 1990-09-13 1993-06-01 Children's Hospital Medical Center Of North California Method for preventing malaria
US5439939A (en) * 1992-03-17 1995-08-08 Children's Hospital Medical Center Of Northern California Pharmaceutical compositions and methods using isobutyramide for treating betaglobin disorders
AU679818B2 (en) * 1993-11-10 1997-07-10 Sloan-Kettering Institute For Cancer Research Butyric ester cyto-differentiating agents

Also Published As

Publication number Publication date
BR9507010A (pt) 1997-09-16
EP0793488A1 (en) 1997-09-10
MX9603885A (es) 1997-05-31
US5569675A (en) 1996-10-29
WO1995024189A1 (en) 1995-09-14
CA2184695A1 (en) 1995-09-14
JPH09510202A (ja) 1997-10-14
IL112896A0 (en) 1995-06-29
KR970701540A (ko) 1997-04-12
EP0793488A4 (OSRAM) 1997-09-10
AU1980695A (en) 1995-09-25

Similar Documents

Publication Publication Date Title
CN1148338A (zh) 用羟酸酯提高胎儿血红蛋白水平
CN100335049C (zh) 泻药组合物
CN1220488C (zh) 用于治疗内皮机能障碍的非诺贝特和辅酶q10组合物
CN1496740A (zh) 普罗布考单酯在治疗心血管疾病和炎性疾病中的应用
JP2009537540A (ja) 化学療法および／または放射線療法の副作用を処置するためのｒａｒアンタゴニストまたはｒａｒインバースアゴニストの使用
US20160250339A1 (en) Pegylated Artesunate Derivative, Pharmaceutical Composition and Use Thereof
MX2015003705A (es) Agente terapeutico para dislipidemia.
US20190169148A1 (en) Method for treating pain or associated condition or symptom
CN1345238A (zh) 用于治疗神经病或神经精神疾病的方法
JP5679458B2 (ja) 内臓脂肪重量の低下剤
CN1159305C (zh) 新的2-(n-氰基亚氨基)噻唑烷-4-酮衍生物
CN1638756A (zh) 左旋(r)班布特罗及其药物用途
CN1275961C (zh) 光活双环醇及其制备方法和其药物组合物与用途
CN1146430C (zh) 用穗霉素或其衍生物减轻或防止疼痛的方法
CN1842328A (zh) 可用作抗炎剂的α－氨基酰胺衍生物
CN1108297C (zh) 维甲酰香豆素类化合物及其制备方法和含该化合物的药物组合物
JP4534039B2 (ja) 糖代謝促進剤並びに肥満及び糖尿病治療薬のスクリーニング方法
CN1201447A (zh) 乳酸的丁酸酯前药
CN1732919A (zh) 双环醇在制备预防和/或治疗急性酒精中毒和急慢性酒精性肝损伤药物中的应用
CN1098086A (zh) 壬四烯酸衍生物
CN1631363A (zh) 黄瘤病的预防、治疗剂
CN1187349A (zh) 治疗糖尿病肾病及延缓慢性肾衰的药
JP7257091B2 (ja) 認知症の治療及び予防薬
US20190125721A1 (en) Methods and compositions for treatment of rett syndrome
CN1346347A (zh) 环胺衍生物和它们的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication